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RECOMMENDATIONS ON HRQL/UTILITY DATA
IN 14 EUROPEAN PHARMACOECONOMIC
GUIDELINES
Szende A1, Rentz A2, Kline Leidy N3
1MEDTAP International, London, England; 2MEDTAP
International, Sindelﬁngen, Germany; 3MEDTAP International,
Inc, Bethesda, MD, USA
OBJECTIVES: Health care decision-making processes,
including public reimbursement of pharmaceuticals, fall
under the responsibility of individual European states,
with each country developing its own pharmacoeconomic
evaluation recommendations. Each guideline addresses
HRQL and utility assessment issues but vary in content
and approach. The objective of this study was to provide
an understanding of these differences. METHODS:
MEDLINE and government agency searches were per-
formed to identify pharmacoeconomic guidelines pub-
lished in Europe. Recommendations on HRQL and utility
evaluation were extracted and compared across guide-
lines. RESULTS: Guidelines on conducting health eco-
nomic evaluation studies were found in 14 European
countries. Ten were directly or closely related to the reim-
bursement authorities, while 4 had academic origin. Four
different recommendations were proposed for evaluating
HRQL outcomes: 1) Disease-speciﬁc and generic instru-
ments should be used together (France, The Netherlands,
Poland, Portugal); 2) Either speciﬁc and/or generic instru-
ments should be used depending on the objectives of 
the health economic study (Belgium, Hungary); 3) Only
generic HRQL measures should be used only (Denmark,
Spain); and 4) Three types of HRQL instruments should
be used simultaneously in health economic evaluations:
generic, disease-speciﬁc and utility-based HRQL instru-
ments (Italy). Four countries did not recommend pre-
ferred methods for HRQL evaluation in their guidelines
(Germany, Finland, Norway, UK). With respect to utility
assessment, there appeared to be some consensus across
guidelines: the EQ-5D and the HUI are acceptable instru-
ments for estimating utilities indirectly, while the time-
trade-off and the standard gamble methods are the most
accepted methods for the direct measurement of utilities.
CONCLUSIONS: Although there appears to be agree-
ment on the preferred choice of utility-based instruments,
recommendations for psychometrically-based HRQL
evaluation vary substantially across guidelines published
in various European countries.
CC3
MEASURING POPULATION HEALTH FOR 191
COUNTRIES:WHO METHODS AND RESULTS
Mathers CD, Salomon J, Murray CJ,Tandon A, Sadana R,
Ustun B
World Health Organization, Switzerland, Switzerland
OBJECTIVES: To measure average levels of population
health for 191 WHO Member States in the year 2000 and
for each subsequent year. WHO has recognized the fun-
damental need for cross-population comparable data on
health and various other categories of evidence for health
policy. This paper outlines the conceptual basis for the
description and measurement of health embodied in
recent WHO work. METHODS: WHO has developed
new methods to improve the comparability of self-report
data across countries, and used these in the WHO Multi-
country Household Survey Study to obtain comparable
measures of health state prevalences for 58 countries. For
measurement purposes, health is operationalized in terms
of levels on a core set of health domains, each character-
ized by a single cardinal scale of capacity. Healthy life
expectancy (HALE) estimates are based on analysis of
mortality for 191 countries, disability for 130 causes for
17 regions of the world, and an analysis of 63 health
surveys in 55 countries. RESULTS: HALE at birth ranges
from a low of 39 years for African women to a high of
72 years in developed countries. The equivalent “lost”
healthy years range from 20% of total life expectancy at
birth in Africa to 11–12% in the European and Western
Paciﬁc regions. The sex gap is highest for Eastern Europe
and lowest in North Africa and the Middle East. 
CONCLUSIONS: The new methods used in the WHO
Multi-country Household Survey Study have increased
the comparability of self-report data across countries, a
major step forward in the use of self-reported data on
health. Health is conceptualized as a set of health domain
capacities, rather than of quality of life, well-being or
utility. Building on this experience, WHO is developing
improved health status measurement techniques for a
World Health Survey to be carried out in 2002.
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OBJECTIVE: The objective of this study was to assess
patient-derived utility estimates for clinical and histolog-
ical health states representing variation in chronic hepati-
tis C (CHC) associated disease severity. METHODS: A
total of 428 patients with CHC participated in a cross-
sectional interview-based study using the utility measure-
ment methods rating scale (RS) and EuroQoL (EQ-5D).
Current clinical and histological health status was
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assessed and assigned to an ordinal scale representing
ascending severity of disease. Rating scale was trans-
formed by the Torrance transformation. Multivariate
stepwise regression with a log-transformed outcome was
used to calculate utilities for the health states adjusted for
age, gender, viral status, co-morbidity, and short-term
effect of current antiviral medication. RESULTS: Quality-
of-life values based on RS (r = 0.24; p < 0.001) and EQ-
5D (r = 0.13; p < 0.019) showed signiﬁcant correlation
with the severity of disease scale. Overall, RS resulted in
higher utilities than EQ-5D. Depending on health state
and instrument, utilities ranged from 0.92 (mild hepati-
tis, RS) to 0.72 (hepatocellular carcinoma, EQ-5D).
Short-term relative utility reduction during the time of
treatment with combination therapy was 15% for RS (p
< 0.001) and 14% for EQ-5D (p < 0.001). RS and EQ-
5D were highly and signiﬁcantly correlated (r = 0.64, p <
0.001) suggesting that the results are robust. CONCLU-
SION: Patients with CHC appear to experience a lower
quality of life compared to the general population. This
study suggests that the Torrance transformation of the
rating scale or EuroQoL from patient reports are feasible
and robust instruments for assessing patient preferences
regarding quality of life. These results can be used in cost-
effectiveness analyses in studies of patients with chronic
hepatitis C.
UT5
COMPARISON OF THE SF6D AND THE EQ5D IN
PATIENTS REQUIRING CORONARY
REVASCULARISATION
van Stel HF, Buskens E
University Medical Center Utrecht, Utrecht, Netherlands
OBJECTIVES: Recently, a new index score to measure
health status has been developed based on items from the
SF36, the so-called SF6D. To assess its merits and valid-
ity we compared baseline and change statistics of the
SF6D and the EQ5D in a group of patients undergoing
coronary revascularisation. METHODS: A consecutive
cohort of 535 patients enrolled in a randomised con-
trolled trial comparing off-pump coronary artery bypass
surgery (CABG) with on-pump CABG and percutaneous
transluminalcoronary angioplasty (PTCA) was adminis-
tered the SF-36 and the EQ5D questionnaires pre- and
post-intervention. The SF6D “utility” was computed
according to the scoring system that recently became
available. RESULTS: We observed no differences in
change score across the arms of trials. Therefore, data on
all patients were analysed together. There were more
missing in the SF6D than in the EQ5D: 12.7% versus
4.7%. All baseline and change variables had non-normal
distributions. Although baseline mean values were com-
parable (SF6D 0.625; EQ5D 0.645, t-test: p = 0.09)
median values differed signiﬁcantly (SF6D 0.603; EQ5D
0.691, Wilcoxon matched pairs test: p = 0.0009). Median
change from baseline as measured with the SF6D was sig-
niﬁcantly lower than change as measured with the EQ5D
(0.024 versus 0.052, p = 0.00002). CONCLUSIONS: The
SF6D and the EQ5D appear to result in similar baseline
scores using the recommended mean values. However,
both the median baseline values and change scores dif-
fered signiﬁcantly. This indicates that the SF6D and the
EQ5D measure different concepts of health status and
cannot be used as equivalents.
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IMPROVEMENT IN HEALTH UTILITY AMONG
RHEUMATOID ARTHRITIS (RA) PATIENTS
TREATED WITH ADALIMUMAB (D2E7),A FULLY
HUMAN ANTI-TNF MONOCLONAL ANTIBODY
van de Putte L1, Boggs R2, Sengupta N2, Dietz B3,
Bergemann R4, Rosery H4, Kupper H3
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OBJECTIVES: To establish whether treatment with 
adalimumab (D2E7, Abbott) improves health utility in
patients with moderate/severe RA. METHODS: A total
of 544 active RA patients from 10 European countries,
Canada and Australia were randomized to receive 
adalimumab or placebo (other disease modifying anti-
rheumatic drugs were discontinued). For 474 patients, the
Health Utilities Index-Mark 3 (HUI3) measured health
utility at baseline, month 3 and 6. An HUI3 score of 1
represents perfect health and 0 represents death. HUI3
change from baseline was estimated for each treatment
group in a linear regression controlling for age, sex,
country, and baseline disease severity (measured by the
Disease Activity Score-28). This analysis includes the 430
patients with non-missing values for these variables.
RESULTS: At baseline, HUI3 scores were comparable
across treatment groups, but mean HUI3 (0.266) was far
below population norms (patients with mild RA typically
score above 0.70). Older patients and patients with more
severe arthritis had lower HUI3 (p = 0.034 and p < 0.001,
respectively). U.K. patients had lower HUI3 than patients
from Australia (p = 0.002), Canada (p = 0.011) or
Germany (p = 0.016). Sex was not a signiﬁcant predictor
of baseline HUI3 scores. At month 3, least squares mean
HUI3 scores (controlling for age, sex, country and base-
line disease severity) improved by 0.160 for the 40mg
every other week adalimumab group, a statistically sig-
niﬁcant and clinically meaningful change compared to 
the placebo group’s 0.064 improvement (p = 0.011). At
month 6, the improvement was 0.166 for the 40mg every
other week adalimumab group compared to 0.078 for the
placebo group (p = 0.029). Patients with more severe RA
improved more than others (p < 0.001). Age, sex, and
country were not predictors of improvement. CONCLU-
SIONS: Adalimumab monotherapy improves patients’
health utility by statistically and clinically meaningful
amounts within three months of treatment initiation and
sustains health utility at month 6.
